Marc Vincent Ngo Barcelona

Dr. Marc Vincent Ngo Barcelona

Radiotherapy, José R. Reyes Memorial Medical Center, Manila, Philippines
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Oral Oncology
Verified
Journal Article
Closed access
Marc Vincent Ngo BarcelonaMarc Vincent Ngo Barcelona
Marc Vincent Ngo Barcelona
JWJohn Waldron
John Waldron
BOBrian O’Sullivan
Brian O’Sullivan
JSJie Su
Jie Su
SBScott Bratman
Scott Bratman
SHShao Hui Huang
Shao Hui Huang

25 August 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
Marc Vincent Ngo BarcelonaMarc Vincent Ngo Barcelona
Marc Vincent Ngo Barcelona
NSNoelia Sanmamed Salgado
Noelia Sanmamed Salgado
EVEnrique Gutierrez Valencia
Enrique Gutierrez Valencia
ABAlejandro Berlin
Alejandro Berlin
RGRachel Glicksman
Rachel Glicksman
PCPeter Chung
Peter Chung
We report early toxicity outcomes after institutional implementation of prostate SBRT using 42.7 Gy in seven fractions delivered with either MR-guided adaptive SBRT (MRgSBRT) or CT-guided non-adaptive SBRT (CTgSBRT). Between July 2019 and May 2023, 216 patients received this regimen. Genitourinary (GU) and gastrointestinal (GI) toxicities were retrospectively assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Most patients had intermediate-risk disease (86%), and 14% had high-risk disease. Median prostate volume was 40 mL, and median baseline International Prostate Symptom Score (IPSS) was 8 among patients with available data. MRgSBRT and CTgSBRT were used in 100 (46%) and 116 (54%) patients, respectively. At a median follow-up of 19 months, 12- and 24-month grade ≥ 2 GU toxicity rates were 20.0% and 18.2%, while grade ≥ 2 GI toxicity rates were 3.5% and 3.6%, respectively. No statistically significant platform-related differences were detected; however, these comparisons were exploratory and potentially confounded by nonrandomized platform selection, treatment era, rectal-spacer use, adaptive workflow and differing PTV margins. On univariable analysis, baseline GU symptoms were associated with higher 12-month grade ≥ 2 GU toxicity (OR, 3.68; 95% CI, 1.52–10.37; p = 0.007), while prostate-volume category was not significantly associated with this endpoint.

26 August 2026 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
Marc Vincent Ngo BarcelonaMarc Vincent Ngo Barcelona
Marc Vincent Ngo Barcelona
KKKaushik Jagannath Kataki
Kaushik Jagannath Kataki
FRFadwa Abdel Rahman
Fadwa Abdel Rahman
Fabio Ynoe de MoraesFabio Ynoe de Moraes
Fabio Ynoe de Moraes
BMBarbara Ann Millar
Barbara Ann Millar
MYMichael Yan
Michael Yan